Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2023-02-21 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin Launches Lurasidone Hydrochloride Tablets in the United States.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Lurasidone Hydrochloride Tablets) by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations, specifically Regulation 30, which relates to material events or information. The document does not contain financial statements, detailed financial analysis, or management discussion. It is a corporate announcement about a product launch, not a financial report, earnings release, or regulatory filing of financial data. The document length is 3854 characters, which is relatively short and consistent with a press release or announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2023-02-21 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Lurasidone Hydrochloride Tablets) by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which relates to material events or information. The content is a corporate announcement about a product launch, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data. The document length is 3849 characters, which is relatively short and typical for a press release or regulatory announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into more specific categories like earnings release or capital update.
2023-02-21 English
Lupin Receives EIR from U.S. FDA for its Injectable Facility in Nagpur.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of an Establishment Inspection Report (EIR) from the US FDA for Lupin's injectable facility. It is a disclosure pursuant to SEBI regulations, indicating it is an official announcement to stock exchanges. The document is short (4129 characters) and primarily serves as a notification rather than containing detailed financial data or comprehensive report content. It does not contain financial statements, management discussion, or detailed report data. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2023-02-17 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of the Establishment Inspection Report (EIR) from the US FDA for Lupin's injectable facility. It is a disclosure pursuant to SEBI regulations, indicating it is a regulatory announcement rather than a full report. The document is short (4268 characters) and primarily serves as an announcement of an event (receipt of EIR) rather than containing detailed financial or operational data. There is no indication of financial statements, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure.
2023-02-17 English
Transcript of Q3 FY2023 Earnings Conference Call.
Call Transcript Classification · 100% confidence The document is a transcript of the Q3 FY2023 earnings conference call for Lupin Limited, dated February 10, 2023. It includes detailed discussions by the management about quarterly financial performance, business highlights, product launches, revenue growth, margins, and outlook. The presence of a Q&A session further confirms it is a full transcript of an earnings call. The document references specific quarterly financial results and operational details, which are typical of earnings call transcripts. Therefore, the document fits the category of a Call Transcript (CT).
2023-02-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of the Q3 FY2023 earnings conference call for Lupin Limited, dated February 10, 2023. It includes detailed management commentary on quarterly financial performance, business highlights, product launches, market conditions, and a Q&A session with analysts. The text explicitly states it is a transcript of an earnings conference call, which matches the definition of a Call Transcript (CT). The document contains substantive financial data and management discussion, consistent with a full transcript rather than a brief earnings release or summary. Therefore, the appropriate classification is Call Transcript (CT).
2023-02-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.